AT-13387

CAS : 912999-49-6

Ref. 3D-FA145338

Informations sur le produit

• Nom: AT-13387
• Synonymes: Onalespib, (2,4-Dihydroxy-5-isopropylphenyl)[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone, (2,4-Dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone, 1H-Isoindole, 2-[2,4-dihydroxy-5-(1-methylethyl)benzoyl]-2,3-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-, At 13387X, At-13387, Ati 3387, Methanone, [1,3-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]-, [1,3-Dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]methanone

Description

AT-13387 is a potent and selective HSP90 inhibitor that binds to the ATP binding site of HSP90 with high affinity. It has been shown to inhibit the proliferation of HL-60 cells in vitro. AT-13387 induces apoptosis in cancer cells by inhibiting the signaling pathways involved in regulating cell growth, including the activation of toll-like receptor 4 (TLR4). The efficacy of AT-13387 was evaluated in vivo using an animal model with bowel disease, which showed significant inhibition of tumor growth. AT-13387 also inhibits TLR4 signaling, suggesting that it may be useful for treating bowel disease. AT-13387 is being developed as a potential therapy for cancer and other diseases associated with TLR4 activation.

• Marque: Biosynth

Propriétés chimiques

• Degré de pureté: Min. 95%